OakChart

Lantheus Holdings Inc

LNTHHealthcare·Drug Manufacturers - Specialty & Generic·USA·Mid·NASD·Nov 11 • 3:29 PM ET

101.52-0.10 (-0.10%)
2026-11-11 21:29 CET
Market cap
6,646.09 USD m
Revenue, TTM
1,562.21 USD m
Net income, TTM
269.90 USD m
Free cash flow, TTM
393.09 USD m
EPS diluted, TTM
4.05
P/E
25.04
Compare

Price

LNTH against its 20, 50 and 200-day averages
2050200beatmiss
80.00100.004.1M8.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LNTHclose 101.5220-day 100.4450-day 100.30200-day 92.76101.5252w high

9.2% under the 52-week high of 111.86 on 30 Jun 2026. 52-week low 50.69 on 11 Nov 2025. Last 15 sessions, 2.0% high to low

Volume 0.68× normal · the line is the 50-bar volume average

Profile

LNTH
52-week range, 83% of the way up
50.69111.86

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the following geographical segments U.S. and International. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

IndexRUT
Employees1193
IPOJun 25, 2015
Beta0.03
ATR, 14d0.46
Rel volume0.68
Short float5.77%
Insider own3.52%
Inst own113.29%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap6.64B
Enterprise Value6.58B
Income269.90M
Sales1.56B
Book/sh20.74
Cash/sh10.45
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1193
IPOJun 25, 2015

Ratios

P/E25.04
Forward P/E15.24
PEG1.21
P/S4.25
P/B4.90
P/C9.71
P/FCF16.89
EV/EBITDA17.22
EV/Sales4.21
Quick Ratio3.06
Current Ratio3.25
Debt/Eq0.46
LT Debt/Eq0.46
Option/ShortYes / Yes

Earnings

EPS (ttm)4.05
EPS next Y6.66
EPS next Q1.32
EPS this Y-10.11%
EPS next Y21.92%
EPS next 5Y12.56%
EPS past 3/5Y104.81% -
Sales past 3/5Y18.13% 35.35%
EPS Y/Y TTM69.00%
Sales Y/Y TTM2.38%
EPS Q/Q-20.32%
Sales Q/Q1.54%
EarningsNov 05 BMO
EPS/Sales Surpr.37.10% 9.60%

Ownership

Insider Own3.52%
Insider Trans0.00%
Inst Own113.29%
Inst Trans-0.54%
ROA11.41%
ROE21.81%
ROIC13.64%
Gross Margin61.26%
Oper. Margin18.65%
Profit Margin17.28%
SMA201.08%
SMA501.21%
SMA2009.45%
Trades-

Technical

Shs Outstand65.37M
Shs Float63.10M
Short Float5.77%
Short Ratio3.21
Short Interest3.64M
52W High111.86 -9.24%
52W Low50.69 100.28%
Volatility0.55% 0.42%
ATR (14)0.46
RSI (14)64.89
Beta0.03
Rel Volume0.68
Avg Volume1.13M
Volume714,282

Performance

Perf Week0.38%
Perf Month1.50%
Perf Quarter0.57%
Perf Half Y5.25%
Perf YTD52.55%
Perf Year90.22%
Perf 3Y59.95%
Perf 5Y238.85%
Perf 10Y930.66%
Recom3.00
Target Price104.98
Prev Close101.62
Price101.52
Change %-0.10%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 13, 2026DowngradeMMizuhoOutperform → Neutral$109+7.4%
Feb 26, 2026UpgradeWWilliam BlairMkt Perform → Outperform
Dec 12, 2025UpgradeTTruistHold → Buy$80-21.2%
Oct 08, 2025DowngradeGGoldmanBuy → Neutral$77-24.2%
Aug 12, 2025DowngradeTTruistBuy → Hold$63-37.9%
Dec 18, 2024InitiatedGGoldmanBuy$143+40.9%
Sep 03, 2024InitiatedRRedburn AtlanticBuy$175+72.4%
Jul 10, 2024ReiteratedJJMP SecuritiesMkt Outperform$100 → $130+28.1%
Dec 18, 2023DowngradeWWilliam BlairOutperform → Mkt Perform
Dec 04, 2023InitiatedTTD CowenOutperform$100-1.5%

Peers

Mkt cap
TickerCompanyMkt cap
TLXTelix Pharmaceuticals Ltd ADR3.30B
GEHCGE HealthCare Technologies Inc37.45B
CATXPerspective Therapeutics Inc103.23M
NVSNovartis AG ADR293.44B
AKTSAktis Oncology Inc957.21M
CAHCardinal Health Inc64.03B
RDNTRadnet Inc6.14B
DRTSAlpha Tau Medical Ltd1.30B
RADXRadiopharm Theranostics Ltd ADR12.87M
CLRBCellectar Biosciences Inc11.25M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Blanchfield PaulFormer OfficerFeb 02 '26Proposed Sale66.976,713449,570Feb 02 01:32 PM
Blanchfield PaulFormer OfficerJan 06 '26Proposed Sale69.537,217501,798Jan 06 11:43 AM
Blanchfield PaulOfficerDec 12 '25Proposed Sale66.823,265218,151Dec 12 03:16 PM
Blanchfield PaulFormer OfficerNov 26 '25Proposed Sale58.3111,776686,665Nov 26 10:43 AM
Blanchfield PaulFormer OfficerNov 14 '25Proposed Sale52.7016,530871,106Nov 14 02:13 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 200
  • PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility (PR Newswire)
  • Lantheus Holdings: Q3 Earnings Snapshot (Associated Press)
  • Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals (GlobeNewswire)
  • Lantheus Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting (GlobeNewswire)
  • Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY TruVu (piflufolastat F 18) (GlobeNewswire)
  • Are BZH, LNTH, BGMS Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer (GlobeNewswire)
  • Lantheus Receives Final FDA Approval for BRAVNETSA (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA for the Treatment of GEP-NETs (GlobeNewswire)
  • Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Curium acquisition of Lantheus backed by $5.375B of debt financing (Pitchbook)
  • Lantheus Announces FDA Approval of TAUKLARIFY (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease (GlobeNewswire)
  • Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Lantheus Holdings: Q2 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-051.6801.2250.330389.91355.748
2026Q22026-08-061.5501.3041.111388.18363.2311
2026Q12026-05-071.4601.2291.800377.33354.4812
2025Q42026-02-261.6701.1940.816406.79366.9912
2025Q32025-11-061.2701.2600.410384.01368.3813
2025Q22025-08-061.5701.6751.120378.05387.9413
2025Q12025-05-071.5301.6571.021372.76379.6712
2024Q42025-02-261.5901.543-0.170391.11376.1113
2024Q32024-11-061.7001.5561.794378.73371.2911
2024Q22024-07-311.8001.8300.879394.09382.1211
2024Q12024-05-021.6901.5441.870369.98349.2510
2023Q42024-02-221.7501.4311.475354339.5610
2023Q32023-11-021.4701.3231.884319.95314.269
2023Q22023-08-031.5401.3101.326321.7305.788
2023Q12023-05-041.4701.290-0.041300.78280.688
2022Q42023-02-231.3700.961-1.740263.17244.747

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.1701.1270.789347.34348.73
2020FY0.4700.454-0.249339.41337.51
2021FY0.4900.413-1.056425.21407.4
2022FY4.2203.8360.397935.06916.62
2023FY6.2305.9204.6511,2961,282
2024FY6.7606.7534.3611,5341,520
2025FY6.0805.5753.4101,5421,502
2026FY-5.465--1,494
2027FY-6.663--1,672
2028FY-8.670--1,932
2029FY-7.640--2,002
2030FY-9.870--2,440

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-11410373.34361.54392
2026Q4S2026-11-08610369.12354.2392
2026Q4S2026-11-05810367.56350.9392
2026Q4S2026-11-04800364.34350.9374.84
2026Q4S2026-10-29900371.89350.9432.3
2026Q4S2026-10-281000373.17350.9432.3
2026Q4S2026-10-271010373.17350.9432.3
2026Q4S2026-10-121020373.17350.9432.3
2026Q4S2026-10-111020373.17350.9432.3
2026Q4S2026-09-291021373.17350.9432.3
2026Q4S2026-09-021021373.14350.9432.3
2026Q4S2026-08-141121371.14350.9432.3
2026Q4S2026-08-131111370.63350.9432.3
2026Q4S2026-08-071101369.95350.9432.3

Estimate history

EPS, annual3.171.0260.789-0.249-1.0560.3974.6514.3613.4134.0543
Period201720182019202020212022202320242025TTM
EPS, quarterly1.794-0.171.0211.120.410.8161.81.1110.327
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual331.378343.374347.337339.41425.208935.0611296.4291533.911541.6091562.21
Period201720182019202020212022202320242025TTM
Sales, quarterly378.734391.11372.764378.045384.014406.786377.333388.18389.913
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual37.76538.46639.25166.87567.73968.85169.86370.90571.82765.373
Period201720182019202020212022202320242025MRQ
Shares, quarterly70.85470.90569.15267.98766.29971.82757.83365.26565.373
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,562.211,541.611,533.911,296.43935.06425.21339.41347.34343.37
Cost of Goods Sold Incl. D&A605.15599.66545.62448.84353.36237.51191.10172.53168.49
Gross Profit957.06941.95988.29847.59581.70187.69148.31174.81174.88
Selling, General and Administrative Excl. Other665.74629.74542.43354.18510.81191.38144.96123.15110.40
Research and Development217.82177.31168.1077.71311.6844.9732.7920.0217.07
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income291.33312.21445.87493.4270.89-3.693.3551.6664.49
Interest Expense19.8019.7519.6720.027.187.759.4813.6217.41
Unusual Expense16.685.2740.87128.7835.2971.515.303.200.00
Net Income Before Taxes342.37313.79430.98410.9426.72-75.04-11.4828.6349.55
Income Taxes72.4780.23118.5384.28-1.35-3.761.99-3.049.03
Consolidated Net Income269.90233.56312.44326.6628.07-71.28-13.4731.6740.52
Net Income From Continuing Operations269.90233.56312.44326.6628.07-71.28-13.4731.6740.52
Net Income269.90233.56312.44326.6628.07-71.28-13.4731.6740.52
EPS (Recurring)4.123.474.765.930.75-0.31-0.180.851.03
EPS (Basic, Before Extraordinaries)4.153.464.524.790.41-1.06-0.250.811.06
EPS (Diluted)4.053.414.364.650.40-1.06-0.250.791.03
EBITDA382.23382.31510.49553.46118.8238.6028.0465.0478.35
Non-Operating Income (Expense)87.5226.6045.6566.32-1.707.91-0.05-6.222.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense63.3067.5960.3539.9023.1211.6310.279.126.19
Price To Earnings Ratio25.0625.0614.8643.4234.22--25.9515.24
Price To Sales Ratio4.362.954.183.363.854.592.152.371.80
Gross Margin61.2661.1064.4365.3862.2144.1443.7050.3350.93
Operating Margin18.6520.2529.0738.067.58-0.870.9914.8718.78
Net Margin17.2815.1520.3725.203.00-16.76-3.979.1211.80
Shares Outstanding65.3771.8370.9169.8668.8567.7466.8839.2538.47
Market Capitalization6,646.096,646.096,219.874,246.323,507.681,955.58902.10804.98601.98

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue389.91388.18377.33406.79384.01378.05372.76391.11
Cost of Goods Sold Incl. D&A146.50146.32146.41165.91161.65137.03135.06142.56
Gross Profit243.41241.85230.92240.88222.37241.01237.70248.54
Selling, General and Administrative Excl. Other211.21141.64149.60163.29178.75153.04135.63139.43
Research and Development92.7638.2039.3847.4848.0245.4936.3135.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income32.21100.2281.3377.5843.6287.97102.07109.11
Interest Expense4.944.924.865.084.954.924.805.04
Unusual Expense12.169.54-14.909.88-1.16-14.5714.86116.46
Net Income Before Taxes21.7893.83156.4170.3642.38104.5296.53-0.78
Income Taxes-0.5918.8037.9916.2814.6125.7623.5811.01
Consolidated Net Income22.3775.03118.4254.0927.7778.7572.94-11.79
Net Income From Continuing Operations22.3775.03118.4254.0927.7778.7572.94-11.79
Net Income22.3775.03118.4254.0927.7778.7572.94-11.79
EPS (Recurring)0.451.211.640.920.400.971.171.01
EPS (Basic, Before Extraordinaries)0.341.151.830.820.411.151.06-0.17
EPS (Diluted)0.331.111.800.820.411.121.02-0.17
EBITDA55.01122.81104.01100.4064.02101.20115.69126.40
Non-Operating Income (Expense)6.678.0665.047.752.566.8914.1311.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.2815.8112.6717.5419.3617.6316.7517.51
Price To Earnings Ratio25.0626.7622.5327.9513.6223.2322.3214.86
Price To Sales Ratio4.364.813.232.862.273.794.544.04
Gross Margin62.4362.3061.2059.2157.9163.7563.7763.55
Operating Margin8.2625.8221.5519.0711.3623.2727.3827.90
Net Margin5.7419.3331.3813.307.2320.8319.57-3.01
Shares Outstanding65.3765.2757.8371.8366.3067.9969.1570.91
Market Capitalization6,646.097,222.874,900.364,413.053,487.425,663.556,683.686,219.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments359.12912.81713.66415.6598.5179.6193.12113.5076.39
Short Term Receivables374.03321.26284.29213.4089.3454.0043.5343.7540.26
Inventories64.6768.0364.0335.4835.1335.7429.1833.0226.08
Other Current Assets102.1424.5423.8413.0912.8214.877.085.145.12
Total Current Assets899.961,326.631,085.82677.62235.79184.22172.91195.41147.85
Net Property, Plant & Equipment194.66212.88192.02141.20125.56138.61117.43107.8993.00
Total Investments and Advances43.9241.161.631.592.142.140.000.000.00
Intangible Assets962.30222.95213.17376.47409.70434.6423.0524.8527.51
Deferred Tax Assets109.20205.00150.20110.6562.7670.1571.8381.4587.01
Other Assets17.366.488.3113.7327.8340.0520.6930.2328.49
Total Assets2,227.402,015.111,651.151,321.26863.78869.82405.92439.83383.86
Short Term Debt Incl. Current Port. of LT Debt4.542.842.732.5313.2421.8610.342.752.75
Accounts Payable42.9134.5641.1920.5620.7916.2818.6117.9517.46
Income Tax Payable3.57--------
Other Current Liabilities282.40203.12143.43224.6156.4742.3537.1732.0526.54
Total Current Liabilities333.42240.53187.35247.7090.5080.5066.1152.7646.75
Long Term Debt618.69618.46616.12583.15179.67215.20184.74263.71265.39
Provision for Risks Charges0.1423.3422.9222.5420.8314.0212.8811.5710.41
Deferred Tax Liabilities54.2534.77-------
Other Liabilities131.109.998.8720.71108.3545.8927.5940.7938.01
Total Liabilities1,137.60927.10835.26874.11399.35355.62291.32368.83360.57
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,089.801,088.01815.89447.15464.44514.21114.6071.0023.29
Total Shareholders Equity1,089.801,088.01815.89447.15464.44514.21114.6071.0023.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,089.801,088.01815.89447.15464.44514.21114.6071.0023.29
Total Liabilities & Stockholders Equity2,227.402,015.111,651.151,321.26863.78869.82405.92439.83383.86
Book Value Per Share15.1715.3411.686.496.867.692.921.850.62
Tangible Book Value Per Share1.7812.208.631.030.811.192.331.20-0.11
Full-Time Employees1,193808834698612595508488483
Price to Book Ratio4.905.376.195.504.211.757.028.48-9.84
Return on Assets11.0117.0421.982.57-8.22-2.117.499.8438.57
Return on Equity21.4532.8251.736.16-14.57-4.2934.1285.94-
Return on Invested Capital13.6718.3122.812.72-11.07-1.8510.5812.1142.74
Quick Ratio2.515.235.452.592.221.842.173.082.60
Current Ratio2.705.525.802.742.612.292.623.703.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income269.90233.56312.44326.6628.07-71.28-13.4731.6740.52
Depreciation91.0070.1064.6260.0447.9342.2924.6913.3813.93
Other Funds (Non Cash)66.32109.12193.33145.39328.8793.6228.8816.5614.96
Funds from Operations400.81434.38540.37476.46356.8569.0738.7671.3375.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital8.67-44.232.05-171.20-75.06-15.15-22.369.05-13.97
Cash from Operating Activities409.48390.14542.42305.26281.7853.9216.4080.3861.19
Capital Expenditures-16.39-41.50-79.62-46.55-18.35-12.14-12.47-22.06-20.13
Net Assets From Acquisitions-10.72-575.67-80.91-45.340.000.000.000.00-
Sale of Fixed Assets and Businesses29.520.000.000.000.000.0017.560.001.00
Purchase or Sale of Investments3.56-10.00-83.250.000.000.000.000.000.00
Purchase of Investments-5.00-10.00-83.250.000.000.000.000.00-
Sale Or Maturity of Investments8.560.000.000.000.000.000.000.000.00
Other Uses-0.230.000.000.00-260.000.00-10.000.000.00
Other Sources1.000.0017.7797.841.8015.820.000.000.00
Cash from Investing Activities1.32-627.17-226.015.94-276.553.68-4.91-22.06-19.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-85.03-289.14-93.275.75-66.096.06-3.021.751.58
Repurchase of Common Pref Stock-100.02-300.02-100.000.00-75.000.000.000.000.00
Sale of Common Pref Stock14.9810.886.735.758.916.06-3.021.751.58
Proceedsfrom Stock Options4.723.733.451.931.380.77-3.090.570.43
Issuance or Reduction of Debt, Net-1.02-1.11-0.32-0.72379.95-43.35-15.49-78.17-2.86
Change in Long Term Debt-1.02-1.11-0.32-0.72379.95-43.35-15.49-78.17-2.86
Issuance of Long Term Debt0.000.000.000.00555.340.000.00197.200.00
Reduction of Long Term Debt-1.02-1.11-0.32-0.72-175.38-43.35-15.49-275.38-2.86
Net Financing Active Other Cash Flow-22.32-26.34-22.61-18.09-2.18-2.05-2.13-2.45-3.39
Other Financing Activities Uses-22.32-26.34-22.61-18.09-7.76-2.05-2.13-2.45-3.39
Cash from Financing Activities-108.36-316.58-116.20-13.06311.69-39.33-21.86-78.88-4.67
Exchange Rate Effect-0.81-0.05-1.00-0.09-0.34-0.310.150.08-0.28
Net Change in Cash301.63-553.66199.20298.04316.5917.96-10.22-20.4837.11
Free Cash Flow393.09354.05490.79258.70263.4341.783.9258.3241.06
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow17.3212.8713.0616.8313.6746.67186.2014.1115.06
Deferred Taxes & Investment Tax Credit-21.59-30.03-55.63-48.024.44-1.339.725.76

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments683.61593.30498.58359.12382.01695.57
Short Term Receivables345.68354.06357.15374.03383.25336.58
Inventories64.2157.5561.3464.6762.0462.16
Other Current Assets30.2022.1525.21102.1497.79107.51
Total Current Assets1,123.711,027.06942.29899.96925.091,201.82
Net Property, Plant & Equipment149.63153.27157.56194.66164.07157.73
Total Investments and Advances100.15120.7060.0243.9248.1746.76
Intangible Assets880.24928.38945.46962.30979.59536.82
Deferred Tax Assets121.14102.7289.12109.20107.45138.26
Other Assets55.9858.0060.0317.3652.0234.70
Total Assets2,456.132,414.662,346.592,227.402,276.402,116.08
Short Term Debt Incl. Current Port. of LT Debt0.600.700.804.540.870.80
Accounts Payable47.7048.1145.8842.9166.3040.89
Income Tax Payable3.344.0322.143.571.411.47
Other Current Liabilities294.32282.84264.34282.40278.27236.98
Total Current Liabilities345.97335.68333.17333.42346.84280.13
Long Term Debt623.68624.26624.95618.69618.57614.70
Provision for Risks Charges0.260.140.140.140.140.14
Deferred Tax Liabilities41.1454.0653.5154.2555.08-
Other Liabilities89.3888.75122.54131.10136.5754.33
Total Liabilities1,100.421,102.881,134.301,137.601,157.19949.29
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,355.711,311.781,212.291,089.801,119.211,166.78
Total Shareholders Equity1,355.711,311.781,212.291,089.801,119.211,166.78
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,355.711,311.781,212.291,089.801,119.211,166.78
Total Liabilities & Stockholders Equity2,456.132,414.662,346.592,227.402,276.402,116.08
Book Value Per Share20.7420.1020.9615.1716.8817.16
Tangible Book Value Per Share7.275.874.611.782.119.27
Full-Time Employees---1,193--
Price to Book Ratio4.905.295.003.942.994.86
Return on Assets11.4112.1512.6811.017.7513.36
Return on Equity21.8122.2123.4821.4514.5924.71
Return on Invested Capital1.133.886.453.171.604.42
Quick Ratio3.062.892.642.512.494.07
Current Ratio3.253.062.832.702.674.29

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income22.3775.03118.4254.0927.7778.75
Depreciation22.9022.5822.6822.8320.4113.23
Other Funds (Non Cash)96.53-3.40-58.1331.3326.8812.98
Funds from Operations110.9281.14102.30106.46104.0198.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-8.9411.0722.83-16.291.28-10.93
Cash from Operating Activities101.9792.20125.1390.18105.2987.11
Capital Expenditures-2.05-2.33-3.23-14.20-10.62-7.96
Net Assets From Acquisitions-13.000.000.002.28-308.85-219.10
Sale of Fixed Assets and Businesses0.000.3129.210.000.000.00
Purchase or Sale of Investments8.560.000.00-5.000.000.00
Purchase of Investments0.000.000.00-5.000.000.00
Sale Or Maturity of Investments8.560.000.000.000.000.00
Other Uses-5.650.000.005.410.00-5.41
Other Sources1.000.000.000.000.000.00
Cash from Investing Activities-11.13-2.0225.99-11.51-319.47-232.47
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.166.864.29-99.33-98.11-97.56
Repurchase of Common Pref Stock0.000.000.00-100.02-100.00-100.00
Sale of Common Pref Stock3.166.864.290.681.892.44
Proceedsfrom Stock Options2.13-0.002.590.001.740.00
Issuance or Reduction of Debt, Net-0.20-0.25-0.22-0.35-0.29-0.06
Change in Long Term Debt-0.20-0.25-0.22-0.35-0.29-0.06
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.20-0.25-0.22-0.35-0.29-0.06
Net Financing Active Other Cash Flow-3.42-2.10-15.70-1.10-0.76-0.80
Other Financing Activities Uses-3.42-2.10-15.70-1.10-0.76-0.80
Cash from Financing Activities-0.464.50-11.62-100.79-99.17-98.41
Exchange Rate Effect-0.060.04-0.02-0.76-0.220.83
Net Change in Cash90.3294.72139.47-22.88-313.56-242.95
Free Cash Flow99.9389.87121.9081.3994.6779.14
Price to Free Cash Flow17.3219.3113.2312.478.4312.08

Revenue breakdown

DEFINITY2024: 317.79M 2025: 330.25M
Neuraceq2025: 51.45M
Other Precision Diagnostics2024: 24.23M 2025: 24.62M
Other Radiopharmaceutical Oncology2024: 384.00K
PYLARIFY2024: 1.06B 2025: 989.12M
Strategic Partnerships And Other2024: 38.18M 2025: 59.38M
Techne Lite2024: 95.49M 2025: 86.80M
Non-US2024: 49.22M 2025: 82.73M
UNITED STATES2024: 1.48B 2025: 1.46B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.77%3.6M63.1M1.36M
2026-10-155.77%3.6M63.0M1.33M
2026-09-306.01%3.8M63.0M1.34M
2026-09-156.41%4.0M63.0M1.36M
2026-08-316.72%4.2M63.1M1.33M
2026-08-148.13%5.1M63.1M1.30M
2026-07-3110.02%6.3M63.0M1.03M
2026-07-1510.19%6.4M62.8M976.10K
2026-06-3010.08%6.3M62.8M953.19K
2026-06-159.73%6.1M62.2M933.67K
2026-05-298.72%5.5M62.8M1.01M
2026-05-1510.25%6.4M62.8M980.70K
2026-04-309.03%5.7M62.8M927.39K
2026-04-158.12%5.1M62.9M934.90K
2026-03-318.59%5.4M62.4M984.73K
2026-03-138.85%5.5M62.4M999.77K
2026-02-278.05%5.0M62.4M955.37K
2026-02-137.60%4.9M64.0M954.74K
2026-01-307.56%4.9M64.8M1.08M
2026-01-158.28%5.4M64.8M1.14M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call55.0044.4048.700.003.2460.000.000.994-0.0290.003
call60.0039.4043.700.002.8700.000.000.994-0.0290.003
call65.0034.4038.700.002.5220.000.000.993-0.0290.003
call70.0029.4033.7030.502.1972.000.000.991-0.0290.004
call75.0024.4028.700.001.8900.000.000.990-0.0290.004
call80.0019.4023.700.001.5960.000.000.987-0.0290.005
call85.0014.4018.7015.701.3113.000.000.984-0.0280.006
call90.009.4013.7010.741.0311970.000.979-0.0270.008
call95.004.506.904.500.35936.000.000.936-0.0420.020
call1000.002.200.550.4731.000.000.596-0.1640.062
call1050.002.150.050.7511.000.000.405-0.2400.062
call1100.001.000.000.7650.000.000.288-0.2250.057
call1150.002.150.000.7530.000.000.165-0.1660.040
call1200.002.150.000.9160.000.000.142-0.1830.036
call1250.002.150.001.0640.000.000.126-0.1960.033
call1300.002.150.001.2010.000.000.115-0.2070.031
call1350.002.150.001.3290.000.000.106-0.2160.029
call1400.002.150.001.4490.000.000.100-0.2240.028
call1450.002.150.001.5610.000.000.094-0.2320.027
call1500.002.150.001.6680.000.000.089-0.2390.026
put55.000.000.050.001.5570.000.00-0.006-0.0210.003
put60.000.000.050.852.9100.0015.00-0.083-0.3950.024
put65.000.000.050.002.5600.000.00-0.094-0.3810.027
put70.000.000.050.002.2340.000.00-0.108-0.3650.029
put75.000.000.050.001.9240.000.00-0.124-0.3470.032
put80.000.000.050.001.6290.000.00-0.144-0.3260.036
put85.000.000.050.001.3420.000.00-0.170-0.3000.040
put90.000.000.050.001.0590.000.00-0.208-0.2670.046
put95.000.000.100.050.7715.000.00-0.252-0.1950.051
put1000.002.150.050.4582.000.00-0.376-0.1140.060
put1051.355.600.000.5680.000.00-0.630-0.1810.060
put1106.3010.600.000.8190.000.00-0.788-0.1440.046
put11511.3015.600.001.0320.000.00-0.836-0.1570.039
put12016.3020.600.001.2410.000.00-0.859-0.1730.036
put12521.3025.600.001.4130.000.00-0.874-0.1860.033
put13026.3030.600.001.5720.000.00-0.885-0.1960.031
put13531.3035.600.001.6950.000.00-0.894-0.2060.029
put14036.3040.600.001.8350.000.00-0.900-0.2140.028
put14541.3045.600.001.9860.000.00-0.906-0.2200.027
put15046.3050.600.002.1080.000.00-0.911-0.2260.026

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-08SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-228-KCurrent report2026-10-21SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-02DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-028-KCurrent report2026-10-02SEC
2026-09-23SCHEDULE 13D/ASEC
2026-09-21DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-218-KCurrent report2026-09-17SEC
2026-09-17DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-08DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-04SCHEDULE 13D/ASEC
2026-09-04SCHEDULE 13GSEC
2026-09-04SCHEDULE 13DSEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-02S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-26PREM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-26SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-13DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Ovata Capital Management Ltd28.42%
ABSOLUTE INVESTMENT ADVISERS, LLC16.23%
BlackRock, Inc.12.90%
FARALLON CAPITAL MANAGEMENT, L.L.C.8.58%
Jupiter Topco LLC7.97%
STATE OF WISCONSIN INVESTMENT BOARD6.32%
VANGUARD PORTFOLIO MANAGEMENT LLC4.97%
VANGUARD CAPITAL MANAGEMENT LLC4.50%
AMERICAN CENTURY COMPANIES INC4.33%
STATE STREET CORP3.84%

Funds

Fund% owned
NYLIM MacKay Convertible Fund36.72%
NYLIM VP MacKay Convertible Portfolio29.74%
iShares Convertible Bond ETF18.59%
ABSOLUTE CONVERTIBLE ARBITRAGE FUND16.28%
Columbia Convertible Securities Fund15.36%
State Street(R) SPDR(R) Bloomberg Convertible Securities ETF13.43%
Fidelity Convertible Securities Fund5.65%
Global Opportunities Portfolio4.92%
CALAMOS CONVERTIBLE & HIGH INCOME FUND4.67%
Brigade High Income Fund4.57%

OakChart. LNTH. Cached 15 minutes.